The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia

[1]  M. Fine,et al.  Assessment of mortality after long-term follow-up of patients with community-acquired pneumonia. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  M. Fine,et al.  Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. , 2002, Archives of internal medicine.

[3]  A. Liappis,et al.  The effect of statins on mortality in patients with bacteremia. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  K D Kochanek,et al.  Deaths: final data for 1999. , 2001, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[5]  S. Grundy,et al.  Effect of Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitor Therapy on High Sensitive C-Reactive Protein Levels , 2001, Circulation.

[6]  A. Szczeklik,et al.  Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. , 2001, International journal of cardiology.

[7]  M. Fine,et al.  Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. , 2001, American journal of respiratory and critical care medicine.

[8]  Michael J Fine,et al.  Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  J. Nicolás,et al.  Comparison of systemic cytokine levels in patients with acute respiratory distress syndrome, severe pneumonia, and controls , 2000, Thorax.

[10]  R. Rosenson,et al.  Inhibition of proinflammatory cytokine production by pravastatin , 1999, The Lancet.

[11]  T. Strandberg,et al.  Effect of statins on C-reactive protein in patients with coronary artery disease , 1999, The Lancet.

[12]  M. Pfeffer,et al.  Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. , 1998, Circulation.

[13]  M. Netea,et al.  LPS-induced cytokine production and expression of LPS-receptors by peripheral blood mononuclear cells of patients with familial hypercholesterolemia and the effect of HMG-CoA reductase inhibitors. , 1998, Atherosclerosis.

[14]  M. Fine,et al.  Quality of care, process, and outcomes in elderly patients with pneumonia. , 1997, JAMA.

[15]  M. Fine,et al.  A prediction rule to identify low-risk patients with community-acquired pneumonia. , 1997, The New England journal of medicine.

[16]  A. Puren,et al.  Patterns of cytokine expression in community-acquired pneumonia. , 1995, Chest.

[17]  M. Fine,et al.  Propensity score adjustment for pretreatment differences between hospitalized and ambulatory patients with community-acquired pneumonia. Pneumonia Patient Outcomes Research Team (PORT) Investigators. , 1995, Medical care.

[18]  M. Fine,et al.  Assessing prognosis and predicting patient outcomes in community-acquired pneumonia. , 1994, Seminars in respiratory infections.

[19]  I. Cree,et al.  Phagocyte function and cytokine production in community acquired pneumonia. , 1994, Thorax.

[20]  J. Enders,et al.  Infectious Diseases Society of America. , 1969, Antimicrobial agents and chemotherapy.